Loading
Latest filing published 05 Jan 2026 for Fortress Biotech, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Dov Klein, listed as board member, appears in our data through filings on Fortress Biotech, Inc. shares, published by SEC (Form 4). Between 15 July 2015 and 1 January 2026, the trades on record add up to 20 filings.
Sales make up the whole of the open-market record (2 sales, €28k). Outside the open market, there are 12 share grants.
Most recently, on 5 January 2026, the filings show a share grant in Fortress Biotech, Inc. Filings reach the SEC (Form 4) feed a median of 23 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations